Metronomic Chemotherapy was Originally Designed and first used in 1994 for Early Stage Cancer - why is it Taking so Long to Proceed?
Harvard School of Public Health, 665 Huntington Avenue, Boston
- *Corresponding Author:
- Dr. Michael Retsky, Ph.D
Harvard School of Public Health
665 Huntington Avenue, Boston
E-mail: [email protected]
Received Date: April 30, 2011; Accepted Date: April 30, 2011; Published Date: May 26, 2011
Citation: Retsky M (2011) Metronomic Chemotherapy was Originally Designed and first used in 1994 for Early Stage Cancer - why is it Taking so Long to Proceed? J Bioequiv Availab 3: 00i-0iv. doi: 10.4172/jbb.100000e6
Copyright: © 2011 Retsky M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The bioavailability and bioequivalence of two different film coated tablets containing ethinylestradiol and gestodene were investigated in 36 healthy female volunteers after oral single-dose administration. The study was performed according to a single-center, randomized, single-dose, 2-way cross-over design with a wash-out phase of 28 days. Blood samples for pharmacokinetic profiling were taken postdose up to 72 h (ethinylestradiol) and 96 h (gestodene). Ethinylestradiol and gestodene plasma concentrations were determined with a validated LC-MS/MS method. Bioequivalence between the products was determined by calculating 90% confidence intervals (90% I.C) for the ratio of AUC0-t and Cmax values for the test and reference products, using logarithmic transformed data. The 90% confidence intervals of ethinylestradiol were 98.49% - 109.19%, and 100.62% - 111.69%, respectively. The 90% confidence intervals of gestodene were 94.07% - 105.91%, and 110.19% - 124.73%, respectively. Since the 90% confidence intervals for Cmax and AUC0-t were within the 80 - 125% interval proposed by Food and Drug Administration, it was concluded that the two ethinylestradiol and gestodene formulations are bioequivalent in their rate and extent of absorption.